Why should I take FEMARA instead of tamoxifen?
In a groundbreaking clinical trial, FEMARA was shown to be a more effective treatment option than tamoxifen for postmenopausal women with hormone receptor-positive early stage breast cancer. Compared to tamoxifen, FEMARA helped reduce the risk of cancer coming back by an additional 21%, based on 24 months of treatment1. With Femara, 296 patients out of 4,003 (7.4%) taking FEMARA recurred versus 396 out of 4,007 (9.2%) of patients taking tamoxifen. At 24 months of treatment, FEMARA (166 out of 4,003) had not been shown to significantly reduce the risk of death verus tamoxifen (192 out of 4,007).